Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis
© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd..
BACKGROUND: In epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), brain metastasis is known as a poor prognosis factor. However, prognostic factors in the patients without brain metastasis remain unclear. In this study, we aimed to clarify the differences between metastatic site and prognosis in common EGFR-mutant NSCLC patients without brain metastasis.
METHODS: Chemotherapy-naïve, advanced EGFR-mutant NSCLC patients without brain metastasis diagnosed between January 2010 and March 2016 were enrolled. We evaluated prognosis according to the presence or absence of bone metastases, liver metastasis, and pleural effusion.
RESULTS: A total of 50 EGFR-mutant NSCLC patients without brain metastasis were enrolled. The median progression-free survival and overall survival were significantly shorter in patients with pleural effusion than in those patients without (progression-free survival 7.0 months, 95% confidence interval [CI] 3.7-13.0 vs. 13.0 months, 95% CI 9.1-21.7, hazard ratio [HR] 2.29, 95% CI 1.11-4.73, P = 0.020; overall survival 19.5 months, 95% CI 5.7-28.8 vs. 55.3 months, 95% CI 24.0-not evaluable, HR 3.00, 95% CI 1.35-6.68, P = 0.005). Pleural effusion was an independent factor of poor prognosis for progression-free survival (HR 3.44, 95% CI 1.50-7.88, P = 0.003) and overall survival (HR 2.34, 95% CI 1.00-5.44, P = 0.049).
CONCLUSION: Pleural effusion might be a poor prognosis factor for advanced EGFR-mutant NSCLC patients without brain metastasis treated with first-generation EGFR-tyrosine kinase inhibitors. Further precision medicine according to the metastatic site is required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Thoracic cancer - 10(2019), 3 vom: 01. März, Seite 557-563 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshimura, Akihiro [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.03.2020 Date Revised 09.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1759-7714.12979 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM293002045 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293002045 | ||
| 003 | DE-627 | ||
| 005 | 20231225074347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1759-7714.12979 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0976.xml |
| 035 | |a (DE-627)NLM293002045 | ||
| 035 | |a (NLM)30672656 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshimura, Akihiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2020 | ||
| 500 | |a Date Revised 09.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND: In epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), brain metastasis is known as a poor prognosis factor. However, prognostic factors in the patients without brain metastasis remain unclear. In this study, we aimed to clarify the differences between metastatic site and prognosis in common EGFR-mutant NSCLC patients without brain metastasis | ||
| 520 | |a METHODS: Chemotherapy-naïve, advanced EGFR-mutant NSCLC patients without brain metastasis diagnosed between January 2010 and March 2016 were enrolled. We evaluated prognosis according to the presence or absence of bone metastases, liver metastasis, and pleural effusion | ||
| 520 | |a RESULTS: A total of 50 EGFR-mutant NSCLC patients without brain metastasis were enrolled. The median progression-free survival and overall survival were significantly shorter in patients with pleural effusion than in those patients without (progression-free survival 7.0 months, 95% confidence interval [CI] 3.7-13.0 vs. 13.0 months, 95% CI 9.1-21.7, hazard ratio [HR] 2.29, 95% CI 1.11-4.73, P = 0.020; overall survival 19.5 months, 95% CI 5.7-28.8 vs. 55.3 months, 95% CI 24.0-not evaluable, HR 3.00, 95% CI 1.35-6.68, P = 0.005). Pleural effusion was an independent factor of poor prognosis for progression-free survival (HR 3.44, 95% CI 1.50-7.88, P = 0.003) and overall survival (HR 2.34, 95% CI 1.00-5.44, P = 0.049) | ||
| 520 | |a CONCLUSION: Pleural effusion might be a poor prognosis factor for advanced EGFR-mutant NSCLC patients without brain metastasis treated with first-generation EGFR-tyrosine kinase inhibitors. Further precision medicine according to the metastatic site is required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epidermal growth factor receptor | |
| 650 | 4 | |a metastasis | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a pleural effusion | |
| 650 | 4 | |a prognosis factor | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Gefitinib |2 NLM | |
| 650 | 7 | |a S65743JHBS |2 NLM | |
| 700 | 1 | |a Yamada, Tadaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Taisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Hamashima, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Shiotsu, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yuba, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Takumi, Chieko |e verfasserin |4 aut | |
| 700 | 1 | |a Uchino, Junji |e verfasserin |4 aut | |
| 700 | 1 | |a Hiraoka, Noriya |e verfasserin |4 aut | |
| 700 | 1 | |a Takayama, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thoracic cancer |d 2010 |g 10(2019), 3 vom: 01. März, Seite 557-563 |w (DE-627)NLM251832414 |x 1759-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |g number:3 |g day:01 |g month:03 |g pages:557-563 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1759-7714.12979 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 |e 3 |b 01 |c 03 |h 557-563 | ||